Artoss, a German company founded in 2005 to commercialize NanoBone technology in North American markets, announced that the FDA has cleared NanoBone SBX Putty for standalone use in posterolateral spinal fusion.
NanoBone was tested alone in the American Society for Testing and Materials International standardized animal model and found to be equivalent to the "gold standard" autograft in fusion rate.
NanoBone Bone Graft products have been used in Europe and the U.S. for over 10 years in more than 100,000 clinical cases across all indications and have been made available in the U.S. via Artoss since 2015.